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Was in accordance with your expectations?   
3,08 
Did it take place in a favorable working 
environment? 
  
3,70 
Were the methods adapted to the objectives?   
3,27 
May it entail positive modifications in your 
professional exercise? 
  
3,29 
Does it deserve to be recommended to your 
colleagues? 
  
3,56 
Interest of the subject 3.27 
Quality of the presentation 3.31 
 
Table 1. Average results of the satisfaction questionnaire, 
with answers scored from 0-4, being 0: no satisfaction; and 4: 
extreme satisfaction. 
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Introduction: Stereotactic body radiotherapy (SBRT) is a 
radiation technique designed to administer precisely directed 
high-dose irradiation that tightly conforms the target, in 
order to create a desired radiobiologic response with tumor-
ablative intent, while minimizing radiation dose to 
surrounding normal tissue, within an image-guided course of 
treatment that does not exceed 5 fractions. SBRT in the 
treatment of localized prostate cancer is widely accepted, 
being the second extracranial malignancy treated with this 
technique, with excellent biochemical control rates and low 
and acceptable toxicity outcomes. 
Purpose: To report preliminary clinical and dosimetric 
analysis of stereotactic body radiotherapy treatment for 
organ-confined prostate cancer in a period of 3 years. 
Material/methods: >From May 2011 through May 2014 a total 
of 13 patients with clinically localized prostate cancer were 
treated using a CyberKnife. Four intraprostatic fiducial marks 
were placed via transrectal ultrasound, two at the prostate 
apex and two at the base separated at least by 2 cm, and 
controlled with orthogonal radiography. After five days 
allowing time for possible seed migration, treatment planning 
was performed using a CT scan (1.25 mm). The course of 
radiotherapy consisted of 5 daily fractions of 7.25 Gy for a 
total dose of 36.25 Gy to the prostate PTV; considered an 
α/β of 1.5 the DEQ2Gy results 90.6 Gy. The PTV was defined 
extending the margin of prostate CTV 5 mm on all sides 
except for posteriorly (by the rectum) where a 3 mm margin 
was used. 
Results: Ten patients were low-risk (77%), intermediate-risk 
(23%). The median prescription isodose was 83% [80-87%], the 
prescribed dose reached a median GTV coverage of 99.95% 
[99.84-100%] and PTV coverage of 96.1% [95.1-97.1%]. 
With a median follow-up of 18 months there was no patient 
with PSA failure, showing a progressive reduction in all of 
them. 
Acute Grade I and II urinary toxicities occurred in 32% and 
18% of patients respectively, only 7% of Grade I late urinary 
toxicities were observed with no higher Grade. Rectal acute 
Grade I and II complications were observed in 23% and 7% of 
patients, and no late toxicity. No patients experienced 
Radiation Therapy Oncology Group Grade III or IV 
complications, both late and acute. 
Conclusions: The current evidence supports consideration of 
stereotactic body radiotherapy among the therapeutic 
options for localized prostate cancer. In well selected 
patients SBRT’s advantages of noninvasiveness, delivery 
without anesthesia or hospitalization and its outcomes, 
compares favorably this technique with other definitive 
treatments. The low toxicity and maintained reduction in PSA 
values seen in this serie are highly encouraging, and 
additional follow-up is needed to determine long-term 
biochemical control and maintenance of low toxicity. 
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